New pain relief hope for lung cancer patients: nerve block via port

NCT ID NCT07396558

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a nerve block given through a small port under the skin can help control chest pain in people with advanced lung cancer. The block delivers numbing medicine near the chest wall nerves. Researchers will compare pain levels and side effects in 180 patients receiving this treatment against a historical control group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

local anesthetic (nerve block)

What this could lead to

If it works, this could offer a new way to manage severe cancer pain at home, reducing reliance on painkillers and their side effects.

What could go wrong

This is an early-stage study with no phase, so results are uncertain. The procedure carries risks like infection or nerve damage, and it may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cancer Pain lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hanoi Medical University

    Hanoi, 100000, Vietnam

    Contact Phone: •••-•••-•••• Email: •••••@•••••